Display options
Cite
Porteus MH. Genome Editing of the Blood: Opportunities and Challenges. Curr Stem Cell Rep. 2015;1(1):23-30doi: 10.1007/s40778-014-0003-z.
Porteus, M. H. (2015). Genome Editing of the Blood: Opportunities and Challenges. Current stem cell reports, 1(1), 23-30. https://doi.org/10.1007/s40778-014-0003-z
Porteus, Matthew H. "Genome Editing of the Blood: Opportunities and Challenges." Current stem cell reports vol. 1,1 (2015): 23-30. doi: https://doi.org/10.1007/s40778-014-0003-z
Porteus MH. Genome Editing of the Blood: Opportunities and Challenges. Curr Stem Cell Rep. 2015 Mar 01;1(1):23-30. doi: 10.1007/s40778-014-0003-z. PMID: 26029496; PMCID: PMC4444059.
Copy Download .nbib Format: NLM
Share it on

Curr Stem Cell Rep. 2015 Mar 01;1(1):23-30. doi: 10.1007/s40778-014-0003-z.

Genome Editing of the Blood: Opportunities and Challenges.

Current stem cell reports

Matthew H Porteus

Affiliations

  1. Dept. of Pediatrics MC5462, Stanford University, Stanford, CA 94305, [email protected].

PMID: 26029496 PMCID: PMC4444059 DOI: 10.1007/s40778-014-0003-z

Abstract

The ability to remove blood cells, including hematopoietic stem cells (HSCs), from a person and then re-transplant them (hematopoietic stem cell transplantation (HSCT) is a well-established treatment paradigm that can be used in both the autologous setting or in the allogeneic setting. Using allogeneic HSCT can cure different genetic diseases of the blood but has significant limitations. An alternative to allogeneic HSCT is to transplant genetically modified HSCs instead. A powerful approach to the precision modification of HSCs is to use genome editing whereby the genome is modified with spatial precision (at an exact location) in the genome and sometimes with nucleotide precision (the exact nucleotide changes are introduced). The progress and challenges of genome editing of blood are discussed.

Keywords: CRISPR/Cas9; Genome editing; TAL effector nuclease; engineered nuclease; homologous recombination; non-homologous end-joining; zinc finger nuclease

References

  1. Nat Med. 2006 Apr;12(4):401-9 - PubMed
  2. Blood. 2011 Oct 27;118(17):4599-608 - PubMed
  3. Nature. 2005 Jun 2;435(7042):646-51 - PubMed
  4. N Engl J Med. 2014 Mar 6;370(10):901-10 - PubMed
  5. Nucleic Acids Res. 2011 Nov;39(21):9283-93 - PubMed
  6. Science. 2007 Dec 21;318(5858):1920-3 - PubMed
  7. Nat Biotechnol. 2010 Aug;28(8):839-47 - PubMed
  8. Nature. 2015 Jan 15;517(7534):360-4 - PubMed
  9. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):274-8 - PubMed
  10. Science. 2013 Oct 11;342(6155):253-7 - PubMed
  11. Nat Biotechnol. 2011 Feb;29(2):143-8 - PubMed
  12. N Engl J Med. 2009 Jan 29;360(5):447-58 - PubMed
  13. Stem Cells. 2011 Nov;29(11):1717-26 - PubMed
  14. N Engl J Med. 2009 Feb 12;360(7):692-8 - PubMed
  15. Nat Biotechnol. 2008 Jul;26(7):808-16 - PubMed
  16. Mol Ther. 2014 Apr;22(4):725-33 - PubMed
  17. Blood. 2011 May 26;117(21):5561-72 - PubMed
  18. Cell Stem Cell. 2014 Nov 6;15(5):643-52 - PubMed
  19. Mol Ther. 2014 Apr;22(4):774-85 - PubMed
  20. N Engl J Med. 2014 Oct 9;371(15):1407-17 - PubMed
  21. Science. 2003 May 2;300(5620):763 - PubMed
  22. Nat Rev Microbiol. 2005 Nov;3(11):848-58 - PubMed
  23. Nat Biotechnol. 2007 Nov;25(11):1298-306 - PubMed
  24. Mol Ther. 2013 Apr;21(4):786-95 - PubMed
  25. Nat Genet. 1998 Apr;18(4):325-30 - PubMed
  26. Science. 2013 Aug 23;341(6148):1233158 - PubMed
  27. Sci Transl Med. 2014 Mar 12;6(227):227ra33 - PubMed
  28. Blood. 2012 Nov 8;120(19):3906-14 - PubMed
  29. Mol Med. 1997 Jan;3(1):23-36 - PubMed
  30. Nature. 2014 Jun 12;510(7504):235-40 - PubMed
  31. Science. 2013 Aug 23;341(6148):1233151 - PubMed
  32. Cell Rep. 2014 Apr 10;7(1):293-305 - PubMed
  33. Genome Res. 2010 Jan;20(1):81-9 - PubMed
  34. Nucleic Acids Res. 2014 Jan;42(2):1365-78 - PubMed
  35. N Engl J Med. 2010 Jul 22;363(4):355-64 - PubMed
  36. Nucleic Acids Res. 2014 Jun;42(11):7473-85 - PubMed
  37. Mol Ther. 2006 Feb;13(2):438-46 - PubMed

Publication Types

Grant support